格菲妥單抗 ，Gresonitamab，CAS: 2413817-97-5，AntibodySystem Laboratories

貨號(hào)：DHC90714

產(chǎn)品鏈接：http://www.atagenix.com/product_detail-75430.html

別名：Bispecific, CD20-TCB (2:1), RG-6026, CAS: 2229047-91-8

簡(jiǎn)介：Glofitamab (RO7082859) 是一種與 T 細(xì)胞結(jié)合的雙特異性抗體，具有新穎的2:1 結(jié)構(gòu)，B細(xì)胞上的CD20為二價(jià)，T細(xì)胞上的CD3為一價(jià)。Glofitamab 與惡性細(xì)胞上的CD20 結(jié)合后，可導(dǎo)致T細(xì)胞活化、增殖和腫瘤細(xì)胞殺傷。Glofitamab可誘導(dǎo)復(fù)發(fā)或難治性B細(xì)胞淋巴瘤的持久完全緩解。

貨號(hào)：DHC90714

產(chǎn)品品牌：Antibodysystem

通用名：Glofitamab

純度：>95% by SDS-PAGE.

濃度：1mg/ml

Formulationicon：0.01M PBS, pH 7.4.

內(nèi)毒素：Please contact with the lab for this information.

別名：Bispecific, CD20-TCB (2:1), RG-6026

靶點(diǎn);物種：Human CD20/MS4A1 & CD3E

種類(lèi)：Humanized

受體鑒定：IgG1-kappa-lambda

CAS: 2229047-91-8

存儲(chǔ)條件：
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
Store at +4°C short term (1-2 weeks).
Store at -20 °C 12 months. Store at -80°C long term.

參考文獻(xiàn)：
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. PMID: 36507690Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial. PMID: 33739857Glofitamab CD20-TCB bispecific antibody. PMID: 34263696Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma. PMID: 34941996Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy. PMID: 35626120Novel in Vivo and in Vitro Pharmacokinetic/Pharmacodynamic-Based Human Starting Dose Selection for Glofitamab. PMID: 34953862Engaging results with glofitamab. PMID: 33828233Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment. PMID: 35182296Experiences with Glofitamab Administration following CAR T Therapy in Patients with Relapsed Mantle Cell Lymphoma. PMID: 36078155Engaging results with glofitamab in DLBCL. PMID: 36600006Immunotherapy in indolent Non-Hodgkin's Lymphoma. PMID: 35663281Role of Bispecific Antibodies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the CART Era. PMID: 35928819Bispecific antibodies for the treatment of lymphomas: Promises and challenges. PMID: 34105818Glofitamab therapy for diffuse large B cell lymphoma: latest updates from the 2022 ASH Annual Meeting. PMID: 36895020Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins. PMID: 34491877[Current status and future prospects of diffuse large B-cell lymphoma treatment]. PMID: 36198538Treatments for Relapsed-Refractory Diffuse Large B-cell Lymphoma: A Preliminary Evaluation of the Place in Therapy of Glofitamab, a Bispecific Monoclonal Antibody. PMID: 36726938Promising Immunotherapeutic Modalities for B-Cell Lymphoproliferative Disorders. PMID: 34768899Cross-linking of T cell to B cell lymphoma by the T cell bispecific antibody CD20-TCB induces IFNγ/CXCL10-dependent peripheral T cell recruitment in humanized murine model. PMID: 33406104Obinutuzumab-induced acute thrombocytopenia: Report of two cases and review of literature. PMID: 37143375Advancing drug development in pediatric oncology, a focus on cancer biology and targeted therapies: iMATRIX platform. PMID: 36637189